Xyla Foxlin, a YouTube content creator and private pilot known for engineering and aviation content, has publicly documented a multi-year FAA special issuance medical battle that originated not from a psychiatric diagnosis but from physiological side effects following a routine IUD replacement. The mood disruption she experienced was acute and identity-altering, yet when she sought medical guidance, physicians defaulted to antidepressant prescriptions — a path she declined specifically to protect her third-class medical certificate. After posting a video about her experience with women's hormonal health, the content was reported to the FAA, triggering a formal review process that ultimately demanded her complete lifetime medical history, full gynecological records, every therapy note ever taken, college health services documentation, a HIMS psychiatrist evaluation costing $4,000 for a single 60-minute session, and a two-day HIMS neuropsychologist evaluation. The FAA ultimately denied her medical on the basis of those submissions before she retained an aviation attorney, spent five to six months constructing a formal appeal, and received a special issuance from the Federal Air Surgeon. She now flies under BasicMed.
The case illustrates a tension that aviation medicine practitioners and pilot advocacy groups have long flagged: the FAA's certification framework creates a structural disincentive for pilots to seek mental health care. Foxlin's situation was compounded by the fact that her symptoms were hormonally driven and not indicative of a disqualifying psychiatric condition, yet the HIMS pipeline — designed for evaluating conditions such as substance use disorders and serious affective disorders — treated her case with the same procedural weight. For working pilots operating under Part 91, 135, or airline certificates, the financial and bureaucratic cost of that process is prohibitive. A $4,000 initial psychiatric evaluation, followed by a multi-day neuropsychological assessment, followed by months of legal representation, represents a barrier that causes pilots to avoid disclosing symptoms or seeking treatment altogether — a safety outcome that is the inverse of what the certification system intends to produce.
The FAA has in recent years acknowledged the mental health disclosure problem, most visibly through the Aviation Workforce and Development Act discussions and the NTSB's repeated recommendations to reform the special issuance process for low-risk mental health conditions. The BasicMed pathway, which Foxlin ultimately utilized, was designed in part to reduce the burden of the traditional medical certification system for private pilots not flying large aircraft or for compensation, but it does not address the chilling effect that HIMS referrals have on pilots who fear that any disclosure will trigger years of scrutiny. Foxlin's case is particularly instructive because her original symptoms were not psychiatric in origin — they were a documented side effect of a medical device change — and yet the system treated her disclosure as a potential disqualifying psychiatric event requiring exhaustive retrospective evaluation.
Foxlin's experience also surfaces a dimension of aviation medicine that receives comparatively little institutional attention: the intersection of women's reproductive health and pilot certification. The FAA's aeromedical framework was developed largely around a pilot population that was historically male, and the protocols for evaluating hormonal health events — including IUD-related mood changes, perimenopause, postpartum conditions, and menstrual-cycle-related physiological effects — remain underdeveloped relative to their prevalence in the growing female pilot population. As the industry pursues workforce expansion and diversity goals, the gap between the lived medical experiences of female pilots and the certification infrastructure designed to evaluate them represents a structural problem that neither BasicMed nor the existing HIMS network is equipped to fully address. Foxlin's public documentation of her case adds to a growing body of pilot testimony that is beginning to pressure regulators toward a more nuanced framework for mental and hormonal health evaluation.